| 1 | Association of the 5-HTT gene-linked promoter region (5-HTTL… (10.2147/pgpm.s23462) | Abstract References ORCID | 141.49 | 76 |
| 2 | Human ABC transporter ABCG2/BCRP expression in chemoresistan… (10.2147/pgpm.s38295) | Abstract References ORCID | 138.38 | 69 |
| 3 | Treatment-resistant schizophrenia: current insights on the p… (10.2147/pgpm.s115741) | Abstract References ORCID | 133.90 | 60 |
| 4 | Pharmacogenomic knowledge gaps and educational resource need… (10.2147/pgpm.s63715) | Abstract References ORCID | 129.32 | 52 |
| 5 | ABCG2 polymorphisms in gout: insights into disease susceptib… (10.2147/pgpm.s105854) | Abstract References ORCID | 128.70 | 51 |
| 6 | Pharmacogenomics of statins: understanding susceptibility to… (10.2147/pgpm.s86013) | Abstract References ORCID | 126.09 | 47 |
| 7 | The current and future state of companion diagnostics (10.2147/pgpm.s49493) | Abstract References ORCID | 125.41 | 46 |
| 8 | UGT1A1 polymorphisms in cancer: impact on irinotecan treatme… (10.2147/pgpm.s108656) | Abstract References ORCID | 119.33 | 38 |
| 9 | Implementation and utilization of genetic testing in persona… (10.2147/pgpm.s48887) | Abstract References ORCID | 114.86 | 33 |
| 10 | CYP3A5 polymorphisms in renal transplant recipients: influen… (10.2147/pgpm.s107710) | Abstract References ORCID | 111.85 | 30 |
| 11 | The <em>HLA-A*31:01</em> allele: influence on ca… (10.2147/pgpm.s108598) | Abstract References ORCID | 109.68 | 28 |
| 12 | Economic evaluations of personalized medicine: existing chal… (10.2147/pgpm.s35063) | Abstract References ORCID | 108.54 | 27 |
| 13 | Immunologic checkpoints in cancer therapy: focus on the prog… (10.2147/pgpm.s53163) | Abstract References ORCID | 108.54 | 27 |
| 14 | Potential utility of precision medicine for older adults wit… (10.2147/pgpm.s101474) | Abstract References ORCID | 107.35 | 26 |
| 15 | Role of pharmacogenomics in the treatment of tuberculosis: a… (10.2147/pgpm.s15454) | Abstract References ORCID | 107.35 | 26 |
| 16 | Clinical potential of novel therapeutic targets in breast ca… (10.2147/pgpm.s52762) | Abstract References ORCID | 107.35 | 26 |
| 17 | Ofatumumab: a novel monoclonal anti-CD20 antibody (10.2147/pgpm.s6840) | Abstract References ORCID | 104.85 | 24 |
| 18 | ABCB1 haplotype and OPRM1 118A &gt; G genotype interacti… (10.2147/pgpm.s29272) | Abstract References ORCID | 103.52 | 23 |
| 19 | CYP2D6 polymorphisms and their influence on risperidone trea… (10.2147/pgpm.s107772) | Abstract References ORCID | 102.13 | 22 |
| 20 | Glioblastoma extracellular vesicles: reservoirs of potential… (10.2147/pgpm.s39768) | Abstract References ORCID | 102.13 | 22 |
| 21 | CYP2C19 polymorphisms in the Thai population and the clinica… (10.2147/pgpm.s42332) | Abstract References ORCID | 100.68 | 21 |
| 22 | The effect of ABCB1 polymorphisms on the outcome of breast c… (10.2147/pgpm.s86672) | Abstract References ORCID | 100.68 | 21 |
| 23 | H3Africa: current perspectives (10.2147/pgpm.s141546) | Abstract References | 100.00 | 99 |
| 24 | Diet and lifestyle factors associated with miRNA expression… (10.2147/pgpm.s117796) | Abstract References ORCID | 99.17 | 20 |
| 25 | MTHFR polymorphisms in childhood acute lymphoblastic leukemi… (10.2147/pgpm.s107047) | Abstract References ORCID | 97.58 | 19 |
| 26 | <p>Diversity In Precision Medicine And Pharmacogenetic… (10.2147/pgpm.s179742) | Abstract References ORCID | 95.91 | 18 |
| 27 | Pharmacogenomics of drug metabolizing enzymes and transporte… (10.2147/pgpm.s18861) | Abstract References ORCID | 95.91 | 18 |
| 28 | Cancer pharmacogenomics, challenges in implementation, and p… (10.2147/pgpm.s62918) | Abstract References ORCID | 95.91 | 18 |
| 29 | ERCC1 and XRCC1 as biomarkers for lung and head and neck can… (10.2147/pgpm.s20317) | Abstract References ORCID | 94.15 | 17 |
| 30 | The role of genetics in pre-eclampsia and potential pharmaco… (10.2147/pgpm.s23141) | Abstract References ORCID | 94.15 | 17 |
| 31 | Association of CYP3A4/5, ABCB1 and ABCC2 polymorphisms and c… (10.2147/pgpm.s44006) | Abstract References ORCID | 92.28 | 16 |
| 32 | Finally sofosbuvir: an oral anti-HCV drug with wide performa… (10.2147/pgpm.s52629) | Abstract References ORCID | 92.28 | 16 |
| 33 | Simeprevir for the treatment of hepatitis C virus infection (10.2147/pgpm.s52715) | Abstract References ORCID | 92.28 | 16 |
| 34 | Mu opioid receptor (OPRM1) as a predictor of treatment outco… (10.2147/pgpm.s33351) | Abstract References ORCID | 90.31 | 15 |
| 35 | Integrating epigenomics into pharmacogenomic studies (10.2147/pgpm.s4341) | Abstract References ORCID License | 90.31 | 7 |
| 36 | Personalized antiplatelet and anticoagulation therapy: appli… (10.2147/pgpm.s52900) | Abstract References ORCID | 90.31 | 15 |
| 37 | Pharmacogenetic polymorphism as an independent risk factor f… (10.2147/pgpm.s117014) | Abstract References ORCID | 88.21 | 14 |
| 38 | Novel treatment strategies in triple-negative breast cancer:… (10.2147/pgpm.s39765) | Abstract References ORCID | 88.21 | 14 |
| 39 | Delivering pharmacogenetic testing in a primary care setting (10.2147/pgpm.s50598) | Abstract References ORCID | 88.21 | 14 |
| 40 | Olaparib in the management of ovarian cancer (10.2147/pgpm.s62809) | Abstract References ORCID | 88.21 | 14 |
| 41 | Emerging biomarkers in the diagnosis of prostate cancer (10.2147/pgpm.s136026) | Abstract References | 86.62 | 53 |
| 42 | Thiopurine S-methyltransferase polymorphisms in acute lympho… (10.2147/pgpm.s108123) | Abstract References ORCID | 85.96 | 13 |
| 43 | Increased risk of hospitalization for ultrarapid metabolizer… (10.2147/pgpm.s114211) | Abstract References ORCID | 85.96 | 13 |
| 44 | Effects of <em>ABCB1 rs1045642</em> polymorphism… (10.2147/pgpm.s158401) | Abstract References ORCID | 85.96 | 13 |
| 45 | Asthma pharmacogenetics and the development of genetic profi… (10.2147/pgpm.s52846) | Abstract References ORCID | 85.96 | 13 |
| 46 | <em>ABCB1</em> genetic variants in leukemias: cu… (10.2147/pgpm.s105208) | Abstract References ORCID | 83.55 | 12 |
| 47 | Role of cytochrome P450 genotype in the steps toward persona… (10.2147/pgpm.s15497) | Abstract References ORCID | 83.55 | 12 |
| 48 | Personalized therapy algorithms for type 2 diabetes: a pheno… (10.2147/pgpm.s50288) | Abstract References ORCID | 83.55 | 12 |
| 49 | Determinants to optimize response to clopidogrel in acute co… (10.2147/pgpm.s5056) | Abstract References ORCID | 83.55 | 12 |
| 50 | Targeted therapies with companion diagnostics in the managem… (10.2147/pgpm.s56055) | Abstract References ORCID | 83.55 | 12 |